{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:55:23Z","timestamp":1790607323745,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Foundation of Korea","award":["NRF-2023R1A2C1007013"],"award-info":[{"award-number":["NRF-2023R1A2C1007013"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002460","name":"Chung-Ang University","doi-asserted-by":"publisher","award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"10.13039\/501100002460","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/01r024a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Chung-Ang University","id":[{"id":"https:\/\/ror.org\/01r024a98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13346-026-02071-3","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:30:49Z","timestamp":1772548249000},"page":"3804-3816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multi-compartment pulsatile drug delivery system for sequential release: in vitro and in vivo evaluation"],"prefix":"10.1007","volume":"16","author":[{"given":"Seung-Dong","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yejin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Soo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-1087","authenticated-orcid":false,"given":"Soyoung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2071_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jconrel.2014.03.054","volume":"190","author":"K Park","year":"2014","unstructured":"Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014;190:3\u20138.","journal-title":"J Control Release"},{"issue":"1\u20132","key":"2071_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.07.026","volume":"398","author":"A Maroni","year":"2010","unstructured":"Maroni A, Zema L, Del Curto MD, Loreti G, Gazzaniga A. Oral pulsatile delivery: rationale and chronopharmaceutical formulations. Int J Pharm. 2010;398(1\u20132):1\u20138.","journal-title":"Int J Pharm"},{"issue":"3","key":"2071_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2011.09.065","volume":"157","author":"SY Lin","year":"2012","unstructured":"Lin SY, Kawashima Y. Current status and approaches to developing press-coated chronodelivery drug systems. J Control Release. 2012;157(3):331\u201353.","journal-title":"J Control Release"},{"issue":"10","key":"2071_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29064","volume":"10","author":"A Rajput","year":"2024","unstructured":"Rajput A, Pingale P, Telange D, Musale S, Chalikwar S. A current era in pulsatile drug delivery system: drug journey based on chronobiology. Heliyon. 2024;10(10):e29064.","journal-title":"Heliyon"},{"issue":"3","key":"2071_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2004.05.015","volume":"98","author":"BB Youan","year":"2004","unstructured":"Youan BB. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J Control Release. 2004;98(3):337\u201353.","journal-title":"J Control Release"},{"issue":"1","key":"2071_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4161\/biom.1.1.17717","volume":"1","author":"D Jain","year":"2011","unstructured":"Jain D, Raturi R, Jain V, Bansal P, Singh R. Recent technologies in pulsatile drug delivery systems. Biomatter. 2011;1(1):57\u201365.","journal-title":"Biomatter"},{"issue":"4","key":"2071_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1517\/17425240902895972","volume":"6","author":"N Saigal","year":"2009","unstructured":"Saigal N, Baboota S, Ahuja A, Ali J. Multiple-pulse drug delivery systems: setting a new paradigm for infectious disease therapy. Expert Opin Drug Deliv. 2009;6(4):441\u201352.","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"2071_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/jps.10336","volume":"92","author":"T Sawada","year":"2003","unstructured":"Sawada T, Sako K, Yoshihara K, Nakamura K, Yokohama S, Hayashi M. Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam. J Pharm Sci. 2003;92(4):790\u20137.","journal-title":"J Pharm Sci"},{"key":"2071_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/DHPS.S71976","volume":"7","author":"JL Goldstein","year":"2015","unstructured":"Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31\u201341.","journal-title":"Drug Healthc Patient Saf"},{"key":"2071_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114147","volume":"180","author":"S Bindu","year":"2020","unstructured":"Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol. 2020;180:114147.","journal-title":"Biochem Pharmacol"},{"key":"2071_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030152","author":"TH Kim","year":"2018","unstructured":"Kim TH, Thapa SK, Lee DY, Chung SE, Lim JY, Jeong HM, et al. Pharmacokinetics and anti-gastric ulceration activity of oral administration of aceclofenac and esomeprazole in rats. Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/pharmaceutics10030152.","journal-title":"Pharmaceutics"},{"issue":"1","key":"2071_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","volume":"19","author":"JM Shin","year":"2013","unstructured":"Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25\u201335.","journal-title":"J Neurogastroenterol Motil"},{"issue":"8","key":"2071_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF03262111","volume":"28","author":"KA Lyseng-Williamson","year":"2012","unstructured":"Lyseng-Williamson KA, Dhillon S. Fixed-dose naproxen\/esomeprazole magnesium: a guide to its use to treat arthritic symptoms and reduce gastric ulcer risk. Drugs Ther Perspect. 2012;28(8):1\u20135.","journal-title":"Drugs Ther Perspect"},{"issue":"5","key":"2071_CR14","doi-asserted-by":"publisher","first-page":"e0216875","DOI":"10.1371\/journal.pone.0216875","volume":"14","author":"S Shin","year":"2019","unstructured":"Shin S, Kim TH, Jeong SW, Chung SE, Lee DY, Kim DH, et al. Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs. PLoS One. 2019;14(5):e0216875.","journal-title":"PLoS One"},{"key":"2071_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25102330","author":"HM Jeong","year":"2020","unstructured":"Jeong HM, Weon KY, Shin BS, Shin S. 3D-printed gastroretentive sustained release drug delivery system by applying design of experiment approach. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25102330.","journal-title":"Molecules"},{"key":"2071_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2023.166003","volume":"902","author":"C Jim\u00e9nez-Arroyo","year":"2023","unstructured":"Jim\u00e9nez-Arroyo C, Tamargo A, Molinero N, Reinosa JJ, Alcolea-Rodriguez V, Portela R, et al. Simulated gastrointestinal digestion of polylactic acid (PLA) biodegradable microplastics and their interaction with the gut microbiota. Sci Total Environ. 2023;902:166003.","journal-title":"Sci Total Environ"},{"key":"2071_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.addr.2016.06.018","volume":"107","author":"B Tyler","year":"2016","unstructured":"Tyler B, Gullotti D, Mangraviti A, Utsuki T, Brem H. Polylactic acid (PLA) controlled delivery carriers for biomedical applications. Adv Drug Deliv Rev. 2016;107:163\u201375.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"2071_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0278-6915(02)00258-2","volume":"41","author":"CC DeMerlis","year":"2003","unstructured":"DeMerlis CC, Schoneker DR. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol. 2003;41(3):319\u201326.","journal-title":"Food Chem Toxicol"},{"key":"2071_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ma14061350","author":"B Basa","year":"2021","unstructured":"Basa B, Jakab G, K\u00e1llai-Szab\u00f3 N, Borb\u00e1s B, F\u00fcl\u00f6p V, Balogh E, et al. Evaluation of biodegradable PVA-based 3D printed carriers during dissolution. Materials. 2021. https:\/\/doi.org\/10.3390\/ma14061350.","journal-title":"Materials"},{"key":"2071_CR20","unstructured":"Food and Drug Administration. Bioanalytical method validation guidance for industry. US Department of Health and Human Services. 2018;1\u201341."},{"issue":"1","key":"2071_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijpharm.2017.03.047","volume":"523","author":"H Van Nguyen","year":"2017","unstructured":"Van Nguyen H, Baek N, Lee BJ. Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion. Int J Pharm. 2017;523(1):189\u2013202.","journal-title":"Int J Pharm"},{"issue":"12","key":"2071_CR22","doi-asserted-by":"publisher","first-page":"22833","DOI":"10.3390\/molecules201219884","volume":"20","author":"TS Gaaz","year":"2015","unstructured":"Gaaz TS, Sulong AB, Akhtar MN, Kadhum AA, Mohamad AB, Al-Amiery AA. Properties and applications of polyvinyl alcohol, halloysite nanotubes and their nanocomposites. Molecules. 2015;20(12):22833\u201347.","journal-title":"Molecules"},{"issue":"3","key":"2071_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1365-2036.2010.04378.x","volume":"32","author":"JL Goldstein","year":"2010","unstructured":"Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Hwang C, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010;32(3):401\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2071_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","volume":"101","author":"JM Scheiman","year":"2006","unstructured":"Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101(4):701\u201310.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2071_CR25","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2460\/ajvr.1981.42.09.1615","volume":"42","author":"HH Frey","year":"1981","unstructured":"Frey HH, Rieh B. Pharmacokinetics of naproxen in the dog. Am J Vet Res. 1981;42(9):1615\u20137.","journal-title":"Am J Vet Res"},{"issue":"4","key":"2071_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2165\/00003088-199732040-00002","volume":"32","author":"NM Davies","year":"1997","unstructured":"Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997;32(4):268\u201393.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2071_CR27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1248\/cpb.20.1457","volume":"20","author":"RA Runkel","year":"1972","unstructured":"Runkel RA, Kraft KS, Boost G, Sevelius H, Forchielli E, Hill R, et al. Naproxen oral absorption characteristics. Chem Pharm Bull (Tokyo). 1972;20(7):1457\u201366.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"4","key":"2071_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00535-014-1032-1","volume":"50","author":"SD Syer","year":"2015","unstructured":"Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, et al. Nsaid enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015;50(4):387\u201393.","journal-title":"J Gastroenterol"},{"key":"2071_CR29","first-page":"123","volume":"7","author":"EK Cook","year":"2016","unstructured":"Cook EK, Satake N, Sykes BW, Bennett EL, Mills PC. Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs. Vet Med (Auckl). 2016;7:123\u201331.","journal-title":"Vet Med (Auckl)"},{"key":"2071_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113668","volume":"193","author":"Y Yang","year":"2021","unstructured":"Yang Y, Li X, Zhou Q, Sun L, Zhang T. Simultaneous determination of naproxen and esomeprazole in beagle dog plasma by supercritical fluid chromatography-tandem mass spectrometry coupled with evaporation-free liquid-liquid extraction. J Pharm Biomed Anal. 2021;193:113668.","journal-title":"J Pharm Biomed Anal"},{"key":"2071_CR31","unstructured":"Australian Government Department of Health and Ageing TGA. Australian Public Assessment Report for Naproxen\/Esomeprazole. Canberra, Australia: Australian Government Department of Health and Ageing, Therapeutic Goods Administration; 2011. Report No.: PM 2010\u201300846\u20133\u20133."},{"key":"2071_CR32","unstructured":"Drugs.com. Vimovo: Package Insert \/ Prescribing Information Greenwood Village, CO, USA2024 [cited 2025 30 July]. Available from: https:\/\/www.drugs.com\/pro\/vimovo.html."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02071-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02071-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02071-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:58:43Z","timestamp":1790603923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02071-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2071"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02071-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not involve human subjects. All institutional and national guidelines for the care and use of laboratory animals were followed. The animal studies were approved by the Institutional Animal Care and Use Committee of HLB Biostep (KNOTUS IACUC 22-KE-0043, KNOTUS IACUC 23-KE-0207).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve human subjects.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no relevant financial or non-financial interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}